Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
A coalition of 10 groups spanning hospitals, health insurers and generic-drug makers sent a letter to Congressional leaders Tuesday asking it to examine Allergan's controversial patent deal with a Native American tribe, adding voices to a growing chorus denouncing the arrangement.
"This issue deserves the prompt attention of Congress, and we encourage you to vigorously apply your oversight authority," wrote the group, which included America's Health Insurance Plans, American Hospital Association and the Association for Accessible Medicines.
The letter came after at least nine congressmen already raised objections to the deal, in which Allergan transferred patents to its $1.4 billion eye drug Restasis to the Saint Regis Mohawk Tribe, whose sovereign immunity could shield it from certain patent challenges from generic-drug makers. The industry groups, in their letter, argued more companies will follow suit if Allergan is successful.
"Allergan's transfer of patent ownership rights to the Saint Regis tribe is a brazen attempt to circumvent U.S. law and engineer a mechanism to maintain monopolistic high drug prices," the group wrote.
It compared the move to another that drew negative publicity to the pharmaceutical industry in years past: tax inversions (something Allergan, in an earlier iteration of the company, did to headquarter the company in a country with a lower corporate tax rate), suggesting "Allergan's scheme may be the first ever 'IP Inversion.'"
The group also sought to tie Allergan in with the industry's most infamous examples of high drug prices: Daraprim, made famous when Martin Shkreli's company Turing raised its price by 5,000 percent, and the EpiPen, sold by Mylan.
"Given the ongoing concern about drug costs, it warrants mention that Restasis generates more in annual revenue than both of those products combined," the group wrote.
Allergan declined to comment on the letter. In an op-ed in the Wall Street Journal Monday, CEO Brent Saunders said the transfer was a way to protect the company's intellectual property "from unfair challenges," saying IPR creates a disadvantage for biopharma innovators and patients.
Analysts and investors originally applauded Allergan for the deal, which was announced Sept. 8, calling it creative. But since then Allergan's stock has declined 7 percent as criticism has mounted.
The company also is defending the same patents against the same generic-drug challengers in federal court, under a process established in the 1984 Hatch-Waxman law. Saunders has also argued that working with the tribe to dismiss the IPR challenges is a way to avoid "double jeopardy" on the same patent battle.